186895-85-2

Basic information

• Product Name: 4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine
• Synonyms: 1-(1,1-Dimethylethyl)-3-(phenylmethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;1-B-PP1;4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine;4-Amino-1-tert-butyl-3-benzylpyrazolo[3,4-d]pyrimidine
• CAS NO: 186895-85-2
• Molecular Formula: C₁₆H₁₉N₅
• Molecular Weight: 281.35556
• Product Categories: All Inhibitors;Bases & Related Reagents;Inhibitors;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals;Tyrosine Kinase Inhibitors;Inhibitors, Nucleotides, Bases & Related Reagents, Pharmaceuticals, Intermediates & Fine Chemicals, Tyrosine Kinase Inhibitors
• Mol File: 186895-85-2.mol

Chemical Properties

• Melting Point: 137-139°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly, Sonicated), Ethyl Acetate (Slightly), Methanol (Slightly, Sonica
• CAS DataBase Reference: 4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine(186895-85-2)
• EPA Substance Registry System: 4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine(186895-85-2)

Safety Data

• Hazardous Substances Data: 186895-85-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine is used as a tyrosine kinase inhibitor for its potential role in the development of targeted therapies against various diseases, including cancer. Its ability to inhibit tyrosine kinases can help regulate cell signaling pathways, making it a promising candidate for drug discovery and development.
Used in Chemical Research:
As a derivative of 4-aminopyrazolo[3,4-d]pyridine, 4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine can be utilized in chemical research to explore its properties, reactivity, and potential applications in the synthesis of other bioactive compounds. Its unique structure and functional groups make it an interesting subject for further investigation and development.
Used in Drug Development:
4-Amino-1-tert-butyl-3-(3-benzyl)pyrazolo[3,4-d]pyrimidine can be employed in drug development as a lead compound or a building block for the design and synthesis of novel therapeutic agents. Its tyrosine kinase inhibitory activity can be leveraged to develop drugs targeting specific diseases, such as cancer, by modulating the activity of key enzymes involved in disease progression.

Upstream product

• 77287-34-4 formamide 
• 476371-60-5 2-phenylacetylmalononitrile 
• 103-80-0 phenylacetyl chloride 
• 103-82-2 phenylacetic acid 
• 1151649-93-2 (4-amino-1-tert-butyl-1H-pyrazolo[3,4-d]-pyrimidin-3-yl)-phenyl-methanol 

Relevant articles and documents

Discovery of a potent protein kinase D inhibitor: insights in the binding mode of pyrazolo[3,4-d]pyrimidine analogues

In this study, we set out to rationally optimize PKD inhibitors based on the pyrazolo[3,4-d]pyrimidine scaffold. The lead compound for this study was 1-NM-PP1, which was previously found by us and others to inhibit PKD. In our screening we identified one compound (3-IN-PP1) displaying a 10-fold increase in potency over 1-NM-PP1, opening new possibilities for specific protein kinase inhibitors for kinases that show sensitivity towards pyrazolo[3,4-d]pyrimidine derived compounds. Interestingly the observed SAR was not in complete agreement with the commonly observed binding mode where the pyrazolo[3,4-d]pyrimidine compounds are bound in a similar fashion as PKD's natural ligand ATP. Therefore we suggest an alternate binding mode where the compounds are flipped 180 degrees. This possible alternate binding mode for pyrazolo[3,4-d]pyrimidine based compounds could pave the way for a new class of specific protein kinase inhibitors for kinases sensitive towards pyrazolo[3,4-d]pyrmidines.

MODULATION OF PROTEIN TRAFFICKING

Compounds and compositions are provided for treatment or amelioration of one or more disorders characterized by defects in protein trafficking. A method of treating a disorder characterized by impaired protein trafficking includes administering to a subject or contacting a cell with a compound of Formula I: [formula here] or pharmaceutically acceptable salts or derivatives thereof.